Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years

BACKGROUND: Comparative effectiveness of natalizumab and fingolimod over a follow-up longer than 2 years has been not addressed yet. OBJECTIVES: To compare the effect on no evidence of disease activity (NEDA-3) in relapsing-remitting multiple sclerosis (RRMS) patients treated with natalizumab or fin...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra, Tommaso, Caputo, Francesca, Orlando, Bianca, Paolicelli, Damiano, Trojano, Maria, Iaffaldano, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519830/
https://www.ncbi.nlm.nih.gov/pubmed/33677753
http://dx.doi.org/10.1007/s10072-021-05127-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519830/
https://www.ncbi.nlm.nih.gov/pubmed/33677753
http://dx.doi.org/10.1007/s10072-021-05127-z

Ejemplares similares